a methylprednisolone-plus-intravenous immunoglobulin combination therapy for Refractory Kawasaki Disease

a methylprednisolone-plus-intravenous immunoglobulin combination therapy for Refractory Kawasaki Disease - Steroid-pulse combination therapy of refractory Kawasaki disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005022

Enrollment

120

Registered

2012-11-01

Start date

2007-04-01

Completion date

Unknown

Last updated

2025-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

refractory Kawasaki disease

Interventions

intravenous immunoglobulin therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria:

Exclusion criteria

Exclusion criteria: a previous diagnosis, the presence of coronary artery aneurysms, and other contraindications to steroid therapy

Design outcomes

Primary

Measure	Time frame
ersistent or recrudescent fever	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Feb 4, 2026